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Vocal fold scarring is an affliction that results in the formation of a disorganized and stiff 
extracellular matrix (ECM) with abnormal ECM component densities & structures 
including a significant increase in collagen deposition.  It is caused by improper healing 
post injury and results in profound changes in the biomechanical properties of the vocal 
folds impairing their ability to generate a normal mucosal wave during phonation. 
 
Finding an effective treatment for vocal fold scarring has been elusive.  Currently, 
treatments seek temporary solutions that correct glottal incompetence and reduce stiffness 
caused by the scar through the augmentation of the vocal folds using various injectable 
materials, such as hyaluronic acid or calcium hydroxylapatite.  These solutions do not 
actually treat the actual scar, but only relieve its effects over the short term seeing as 
current injectable materials readily degrade. 
 
To solve this problem researchers have been testing the impact various therapeutics have 
on helping prevent or regress vocal fold scarring.  Unfortunately, realizing the full 






largest being that, even if anti-scarring agents are directly injected into a vocal fold scar, 
these therapeutics are readily cleared or metabolized by the vocal fold tissue over a short 
period of time.  This necessitates the need to re-inject the therapeutic multiple times in 
order to maintain its efficacy.  Though this is possible, issues of patient safety and 
tolerance quickly become significant problems one must address if one desires to pursue 
such a rigorous treatment method. 
 
The overall goal of my research was to address this issue of effectively delivering 
therapeutics to an area of vocal fold scarring to facilitate healthy unscarred tissue 
regeneration.  To accomplish this goal my early work focused on the development of in 
vitro unscarred and scarred culture systems in which to eventually test our newly 
developed delivery systems.  Initial work with these systems focused on characterizing 
them in order to better understand the role RGD integrin binding site concentration and 
cell phenotype had on directing extracellular matrix gene expression in vocal fold 
fibroblasts.  What we learned was that indeed RGD integrin binding site concentration 
does affect both depending on the circumstances.  With changes in fibroblast phenotype 
from unscarred to scarred resulting in ECM gene up-regulation for all genes tested, 
except for HAS2 and decorin.  Meanwhile, changes in RGD concentration only increased 
elastin and collagen type 3 alpha 1 expression as RGD concentration was increased in 
scarred vocal fold fibroblasts only.  HAS2 was also down-regulated in scarred fibroblasts 
at the highest RGD concentration.  However the other genes tested were unimpacted by 
RGD concentration changes in scarred or unscarred fibroblasts.  This knowledge is 





and scarring, direct cells to regenerate healthy tissues with normal ECM ratios and 
morphologies.  Next, we moved on to developing our drug delivery system initially 
utilizing a nanoparticle based system.  Our nanoparticle system was composed of a poly-
lactic-co-glycolic acid (PLGA) core encapsulated within a shell of poly(N-
isopropyacrylamide (pNIPAM) and had unique properties that were designed to help 
better facilitate more effective delivery of therapeutics including active targeting and the 
ability to respond to dynamic environmental stimuli.  However, concerns arose that the 
small size of the nanoparticles would not allow for an effective amount of drug to be 
loaded into them and that they would more readily degrade and release loaded 
therapeutics due to their high surface to volume ratio.  We, therefore, transitioned to 
using larger hydrogel templated PLGA microparticles instead.  We also moved on to 
testing our ability to actually deliver an effective anti-fibrotic and anti-inflammatory 
agent to scarred vocal fold fibroblasts over the long term.  To do this, the PLGA 
microparticles were loaded with the corticosteroid dexamethasone.  Real-time PCR 
showed that only dexamethasone loaded microparticles proved effective at maintaining 
down regulation in the expression of COL3A1 and COL1A2 over the long term.  While 
an ELISA showed that dexamethasone only decreased the deposition of the pro-
inflammatory cytokine interleukin-6 over the long term, but had no impact on the other 
three pro-inflammatory cytokines tested.  
 
Future work will look at trying to continue to improve the drug delivery platform for use 
in vocal fold scarring by combining the pNIPAM-co-acrylic acid shell, from our core + 





combination would meld the advantages of the larger microparticle size and its ability to 
more readily deliver an effective dose of therapeutic with the many beneficial attributes, 
like targeting and responsiveness to environmental stimuli, of the pNIPAM-co-acrylic 
acid shell.  Furthermore, with the addition of a shell, another level of control over 












CHAPTER 1. INTRODUCTION 
1.1 Background and Significance 
It is estimated that 5-10% of the United States population suffers from some form of 
communication disorder resulting in estimated economic losses of $154 to $186 billion 
per year.
[10]
  These communication disorders can stem from many different sources 
including the impairment of the vocal folds, which are responsible for the generation of 
most human phonation capabilities.  Due to this unique functional role, the vocal folds 
have evolved a compositional structure that provides them with strength,
[1, 2]
  which 
allows them to undergo significant stresses stemming from conversational phonation 
frequencies that range from ~100-300Hz at amplitudes of 1-2mm.
[2]
  While at the same 





1.2 Vocal Fold Structure 
Human vocal folds are composed of many different layers.
[1, 2]
  The first is the epithelium 
layer which serves as a defensive barrier against external environmental factors like 
bacteria or air pollutants.
[1, 2]
  It is composed of stratified squamous epithelia unlike the 
rest of the respiratory tract, which is composed of ciliated columnar epithelia.
[1, 2]
  This 







  The BMZ is mainly composed of ECM components such as high 
amounts of proteoglycans like decorin, heparin sulfate, & chondroitin 4-sulfate as well as 
collagen type I & III and some elastin.
[11-13]
  Inferior to the BMZ is the superficial lamina 
propria layer.  It is one of the most important layers in the vocal folds as this is where the 
mucosal wave is generated and allowed to then propagate through the other layers.
[1, 2]
  
As a result, it must be highly flexible, and is, therefore, composed of only limited 
amounts of mature organized elastin fiber networks & thin bundles of collagen type I & 
III fibers.
[1, 2, 11, 12]
  It also contains significant amounts of the proteoglycan decorin.
[13]
  
Moving deeper we come to the intermediate lamina propria layer, which is composed of 
high levels of elastin, organized into mature organized fiber networks, as well as 
hyaluronan.
[1, 2, 11]
  Little collagen type I or III and proteoglycans are present in the 
intermediate lamina propria layer, although there is some versican.
[12, 13]
  Inferior to the 
intermediate layer is the deep lamina propria layer, which is composed of significant 
amounts of collagen type I & III and elastin in the form of mature organized collagen or 
elastin fiber networks.
[1, 2, 11, 12]
  Proteoglycans like versican, decorin, chondroitin 4-
sulfate, and biglycan are also present in sizable amounts in the deep lamina propria 
layer.
[13]
  The final layer of the vocal folds is the vocalis muscle which, in tandem with 
other muscles, plays a significant role in controlling the overlying vocal fold layers in 









1.3 Vocal Fold Scarring 
As the previous section elucidated, the structure of the vocal folds is highly complex due 
in part to the unique functional role they play in allowing the controlled generation of the 
wide range of sounds in human phonation.  Unfortunately, this also means that any 
damage to the vocal folds can result in significant, if not complete, loss of a human’s 
ability to phonate.  Such damage can come from many sources including intubation, 
vocal misuse or phonotrauma, gastroesophageal reflux disease, chemical irritants like 
smoking or air pollution, blunt/penetrating trauma, cancer, or various surgical 
treatments.
[2]
  How the vocal folds respond to these damaging events depends on the 
extent of the damage as well as how often the damaging event occurs.
[15]
  If the damaging 
event is mild and occurs infrequently then the normal vocal fold wound healing process 
will be able to regenerate the highly tuned ECM structure with no adverse complications.  
However, if the damaging event is significant or occurs frequently then the normal vocal 
fold wound healing process will be unable to regenerate the highly tuned ECM structure 
causing pathological disorders to manifest. 
 
One such pathological disorder is vocal fold scarring and it is one of the most difficult to 
treat.
[3]
  Vocal fold scarring usually occurs due to external trauma, chronic vocal misuse, 
a major or chronic inflammation event, or iatrogenic causes.
[2, 16, 17]
  Once formed the 
vocal fold scar effects the patient by manifesting as vocal fatigue, increased phonation 
effort, hoarseness, breathing difficulties or shortness of breath usually due to excessive 
air loss during phonation, glottal incompetence, or if scarring is severe enough, complete 
loss of phonation capabilities.
[2, 3]





injury the vocal fold wound healing process is unable to properly regenerate the normal 
ECM structures that make up the layers of the vocal fold.
[2, 16, 17]
   
 
Instead, what occurs is the formation of a disorganized ECM that does not exhibit the 
normal layered structure or ECM component distribution.
[2, 16, 17]
  This change in 
relationship between the various ECM component densities and organization results in 
profound changes in the biomechanical properties, like viscosity and shear strength, of 
the vocal folds, thereby resulting in impairment of normal mucosal wave generation.
[2, 16, 
17]
  Since the mucosal wave is initially propagated in the superficial layer of the lamina 
propria, it is this layer that is most affected by changes in its ECM composition.
[1, 2, 16, 17]
 
 
Although we know that vocal fold scarring causes dysphonia (loss of normal vocal 
function) due to improper regeneration of the ECM, much research is still being done in 
order to better understand the biological processes behind vocal fold scar formation.  To 
this end, researchers have learned from various animal models that the regeneration of the 
ECM post injury is a dynamic process with various ECM components being expressed at 
various time points during the wound healing process.
[16, 17]
  Overall, it has been shown in 
these animal models that vocal fold scar tissue is characterized by an increase in collagen 
that is present in thick disorganized bundles and low levels of elastin that is present in a 
fragmented network of disorganized fibers.
[17]
  High levels of fibronectin and low levels 
of hyaluronan are also present.
[17]
  Decorin and fibromodulin are also decreased in the 
rabbit model.
[17]





understanding of vocal fold scarring and potentially better treatments that prevent scar 
formation or are able to revert scarred tissue back to a healthy state. 
 
1.4 Current Treatments for Vocal Fold Scarring 
Once a patient has been diagnosed with a vocal fold scar, the severity of the scarring and 
its subsequent impact on phonation must be determined.  To do this a comprehensive 
voice evaluation must be conducted by a speech language pathologist in conjunction with 
a physician specializing in otolaryngology.  The evaluation includes a detailed review of 
the patient’s past medical history including voice use profile, instrumental voice 
assessment, and most importantly a laryngeal videostroboscopy.  Videostroboscopy 
allows the pathologist and the physician to visualize the vocal folds during vibration 
helping them identify decreased mucosal wave or adynamic segments of the vocal folds 
caused by the scar.
[3, 16]
  Depending on these findings direct laryngoscopy using high-
powered microscopy may be warranted in order to fully characterize the nature and 




Once the severity of the vocal fold scar has been ascertained through these diagnostic 
procedures a treatment regimen can be developed.  For example, if vocal fold scarring is 
not severe then voice therapy can be used to alleviate dysphonia caused by the scar.  
Voice therapy may involve patient education aimed at reducing or eliminating 
maladaptive compensatory behaviors that arise due to the scar.
[3, 16]
  It can also be helpful 







However, if vocal fold scarring is severe or voice therapies fail then surgical treatment 
may be necessary. 
 
Surgical treatments mainly revolve around vocal fold augmentation medialization.
[3, 16]
  
This procedure seeks to correct glottal incompetence, that commonly occurs due to vocal 
fold scarring, by injecting a material into the scarred vocal folds in order to medialize 
them and thereby improve phonation capabilities in the patient.
[3, 16]
  The most common 
types of materials used in the clinic as medialization agents include calcium 





1.5 Disadvantages of Current Treatments 
Though vocal fold augmentation medialization with the aforementioned materials has 
proven promising, this treatment for vocal fold scarring induced glottal incompetence is 
not the optimal form of treatment.  First off, the current materials used to medialize the 
vocal folds are all of a temporary nature with the body reabsorbing these materials over a 
rather short period of time, usually within a few months to a year.  This necessitates 
reinjection of these materials into the vocal fold in order for the patient to continue to 
reap the benefits from vocal fold augmentation medialization.
[2]
  Second, some of the 
aforementioned treatments can also cause undesired immune response reactions.
[18]
  For 
example, if bovine collagen is not correctly processed not all of the bovine antigens will 
be removed from it.  As a result, when it is then injected into the human vocal folds, it 





scarring.  Finally, and most importantly, none of these current materials actually facilitate 
the regeneration of the vocal folds back to their normal unscarred state nor could they be 
used to prevent vocal fold scar formation.  As a result, they provide no means of 




1.6 Developing Better Treatments 
To overcome these disadvantages researchers have been trying to engineer better 
materials/treatments utilizing a variety of different methods.  One such method has used 
complex natural decellularized ECMs as opposed to individual ECM derived components, 
like collagen, to facilitate the regeneration of damaged or scarred vocal folds.  These 
decellularized matrices are usually obtained from xenogeneic or allogeneic sources.  For 
example xenogeneic porcine liver-derived ECM has been used to facilitate the successful 
regeneration of injured canine vocal folds.
[19]
  The major advantage of these types of 
matrices is the fact that they inherently contain a heterogeneous mixture of biological 
components that are critical in facilitating normal tissue regeneration.  Disadvantages 
include the fact that current decellularization processes can remove some of the natural 
decellularized ECM’s unique biological components.  However, care must be taken to 
ensure that the decellularization process is still rigorous enough to remove potential 
immunogenic factors, that could induce an undesirable immune response, or viruses, that 
could cause disease.  The most difficult disadvantage to overcome will be how best to 
implant these matrices without damaging the matrix itself or healthy tissue that already 






A second method being explored is the engineering of multi-component synthetic 
hydrogels in order to form a hybrid material that contains the beneficial attributes of each 
component.  For example, chemically modified hyaluronic acid (HA) and gelatin were 
combined to form a hybrid HA-gelatin hydrogel.
[20]
  This hybrid material has beneficial 
attributes of both HA and gelatin.  In the case of HA, one can vary the amount of HA 
crosslinking to tune the biomechanical properties of the hybrid hydrogel.
[20]
  While 
gelatin’s usage can enhance the poor adherence properties of HA.
[20]
  The major 
advantage of this approach is that it allows one, in a highly controlled and reproducible 
manner, to mix, match, and tune mechanical and biological properties to treat vocal fold 
disorders like scarring.  The disadvantages consist of the fact that residual unreacted 
components can prove toxic to cells.  Of greater concern is the number of challenges, like 
scale and cost, that exist with engineering such highly complex multi-component hybrid 
hydrogel systems. 
 
A third method under development involves combination treatments.  Here researchers 
are creating complex systems that combine synthetic or natural materials and biologically 
relevant cell lines or molecules, such as growth factors, in order to address many different 
vocal fold disorders like scarring.  A current example of a combination treatment 
involved combining bone marrow mesenchymal stem cells with a synthetic ECM which, 
when administered to damaged rat vocal folds, promoted healthier deposition of ECM 
versus controls.
[21]
  The advantage of these combination treatments is that they will better 
facilitate the healthy integration of the implant with the host tissue.  The disadvantages 





Furthermore, biologically active components could have undesired off target effects 
outside the vocal folds. 
 
The fourth, and final method discussed here, involves the use of nanoparticles or other 
nano- or micro-structures in order to facilitate the delivery and controlled release of 
relevant biological agents to damaged or diseased vocal folds.
[22, 23]
  For example, PLGA 
nanoparticles loaded with Texas Red-dextran have shown successful release of the Texas 
Red-dextran when injected in vivo into murine vocal folds.
[22]
  While hepatocyte growth 
factor loaded PLGA nanoparticles were shown to reduce procollagen expression in vitro 
by 3T3 fibroblasts signifying successful release of functional hepatocyte growth factor 
from the PLGA nanoparticles.
[22]
  The advantages of this method are that therapeutics 
administered to the vocal folds via nano- or micro-structured delivery systems will help 
protect them from degradation and provide a depot from which the therapeutic can be 
released in a controlled manner over time.  Disadvantages include the fact that the use of 
these nano- or micro-structures as bulking agents, in order to correct the glottal 
incompetence that sometimes results from vocal fold scarring, is questionable as such 
structures are not very conducive for this use. 
 
1.7 Specific Aims 
The goal of this dissertation is to address the gap in effective clinical treatments for vocal 
fold scarring by developing a particle based therapeutic delivery system that will both 
target and deliver therapeutics that can prevent or treat vocal fold scarring.  Such a 






manner.  This is important when one wants to facilitate proper tissue regeneration. To 
achieve this three different specific aims were proposed and completed. 
 
1.7.1 Aim #1 
Characterize the role different concentrations of RGD, an integrin binding site, plays in 
directing extracellular matrix gene expression in scarred and unscarred in vitro culture 
systems of immortalized human vocal fold fibroblasts. 
 
Much work has been done pertaining to the role RGD integrin binding sites play in cell 
growth, proliferation, and motility.
[4-7]
  However, little work has been done to elucidate 
the role that RGD integrin binding sites play in directing ECM gene expression.  Little is 
also known pertaining to how ECM expression changes when a cell’s phenotype changes 
from unscarred to scarred.  This aim sought to address this issue by assessing how 
relative gene expression profiles of ECM components expressed by immortalized human 
vocal fold fibroblasts (I-HVFFs) change based on phenotype, unscarred versus scarred, 
and on the concentration of RGD on which they are grown.  
 
1.7.2 Aim #2 
Develop and characterize a nanoparticle system that resists aggregation caused by 








A novel poly(lactic-co-glycolic acid) (PLGA) core + poly(N-isopropylacrylamide) 
(pNIPAM)-co-acrylic acid (AAc) shell nanoparticle system was synthesized and 
characterized.  A critical characteristic of this system is the ability of the pNIPAM-co-
AAc shell to prevent the aggregation of the PLGA cores during lyophilization without the 
need of cryo-protectants.  Secondly, the addition of the pNIPAM-co-AAc shell imbues 
the overall PLGA core + pNIPAM shell nanoparticle system with more dynamic 
properties including the ability to respond to environmental stimuli.  Thirdly, the addition 
of the acrylic acid monomer to the pNIPAM shell polymer provides a functional handle 
used to append targeting ligands in an acrylic acid monomer concentration dependent 
manner.  Finally, results from in vitro experiments demonstrate the biocompatibility of 
these PLGA core + pNIPAM-co-AAc nanoparticles with cells. 
 
1.7.3 Aim #3 
Evaluate the long-term anti-fibrotic and anti-inflammatory capabilities of the 
corticosteroid dexamethasone on scarred I-HVFFs when released from PLGA hydrogel 
templated microparticles.  
 
Controlling the release of various therapeutics that show promise treating scarring may 
improve their efficacy.  To shed light on this issue we loaded dexamethasone (dM), an 
anti-fibrotic and anti-inflammatory therapeutic, into a hydrogel templated poly-lactic-co-
glycolic acid (PLGA) microparticle (mP) delivery vehicle.  Release studies showed 
successful loading and release profiles of dM from three types of PLGA microparticles 






high, were varied.  To ascertain dM’s anti-fibrotic and anti-inflammatory effectiveness 
when released from PLGA mPs over the long term, they were exposed to scarred human 
vocal fold fibroblasts in vitro.  Marked down regulation in collagen in scarred fibroblasts 
was only seen in those treated with dM loaded mPs, indicating dM maintained its anti-
fibrotic activity over the long term.  While ELISAs illustrated that of the 4 pro-
inflammatory cytokines tested dM’s anti-inflammatory affects over the long term were 
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CHAPTER 2.  CHARACTERIZING THE IMPACT RGD CONCENTRATION PLAYS 
IN DIRECTING ECM GENE EXPRESSION IN SCARRED AND UNSCARRED 
IN VITRO VOCAL FOLD FIBROBLAST CULTURE SYSTEMS 
2.1 Abstract 
The impact of RGD integrin binding site concentration and cell phenotype on directing 
extracellular matrix (ECM) gene expression in vocal fold fibroblasts is little understood.  
Less is known about cell response to RGD concentration on a biomaterial when 
fibroblasts are in a scar-like environment compared to a healthy environment.  We 
investigated the effects of varying RGD integrin-binding peptide surface concentration 
(0.01mM – 1mM), on ECM gene expression of elastin, collagen type 3 alpha 1, decorin, 
fibronectin, hyaluronan synthase 2, and collagen type 1 alpha 2 in scarred and unscarred 
immortalized human vocal fold fibroblasts (I-HVFFs).  Phenotype and RGD 
concentration affected ECM gene expression.  Phenotype change from unscarred to 
scarred resulted in ECM gene up-regulation for all genes tested, except for decorin.  
Systematically altering RGD concentration affected the expression of elastin and collagen 
type 3 alpha 1 in a scarred phenotype but not unscarred.  Specifically greater up-
regulation in gene expression was observed with higher RGD concentrations. This 
research demonstrates that controlling RGD concentration may influence ECM gene 







implanted into sites of tissue damage and scarring, direct cells to regenerate healthy 
tissues with normal ECM ratios and morphologies. 
 
2.2 Introduction 
Much work has been done on the role of RGD integrin binding sites in cell binding, 
growth, proliferation, and motility.
[1-4]
  As a result RGD has been incorporated into 
many different types of materials in order to facilitate the binding and proliferation of 
cells to normally non-adherent materials.
[5-7]
  For example, non-adherent hyaluronic 
acid has been modified with RGD to develop an adherent, bioactive material for 
correcting vocal fold defects.
[7]
 However, improving cell adherence does not usually 
result in the proper full restoration of healthy tissues, vocal folds or otherwise.  That 
is because healthy tissues are complex heterogeneous structures that require the 
expression and deposition of ECM components in normal ratios and morphologies in 
order to maintain their proper function. 
 
Researchers have been working to develop materials that facilitate such regeneration 
via many different methods.  One such method is the use of RGD to modulate the 
expression of genes that play key roles in regeneration of the tissue being studied.  
For example TiO2 nanotube surfaces have been modified with varying amounts of 
RGD.
[8]
  Rat bone marrow stromal cells when grown on these substrates showed a 
dramatic enhancement in the expression of osteogenic genes on nanotube surfaces 
modified with higher concentrations of RGD versus lower.
[8]
  This same trend was 






poly(ethylene glycol) diacrylate hydrogels modified with varying amounts of RGD.
[9]
  
Again, as RGD concentration increased, bone-related marker expression also 
increased.
[9]
  Finally, researchers have also looked at how cell lines from soft tissue 
sources behaved when both RGD concentration and integrin type were varied.
[10]
  
They found that as the adhesiveness of the surface increased, either due to the 
increased RGD or the use of a more adherent integrin, a decrease in overall ECM 




Although RGD’s impact on gene expression has been studied in relation to bone cell 
differentiation and impact on overall ECM production of cells from soft-tissue, gaps 
still exist.
[8-10]
  For one, though we have a gross understanding, as mentioned in the 
third example above, on how RGD concentration impacts overall ECM deposition.  A 
finer break-down of how RGD concentration impacts the expression of individual 
ECM genes would be of greater help in designing better biomaterials that facilitate 
the expression of individual ECM components in healthy ratios.  Furthermore, little is 
understood with regards to how ECM component gene expression is affected by 
changes in a cell line’s phenotype brought on by changes in the environment.  This 
knowledge is especially important to have so one can understand how cells growing 
on RGD modified materials might behave when implanted into a site of tissue 
damage and scarring.  
 
Here we begin to address these issues by growing adherent immortalized human 






polyethylene glycol (PEG) thin film coated glass substrates modified with varying 
concentrations of RGD integrin binding peptide.  Treated I-HVFFs were then probed 
utilizing RT-qPCR to assess the impact of varying RGD concentration and cell 
phenotype on the expression of six ECM genes including elastin (ELN), decorin 
(DCN), fibronectin (FN), collagen type 1 alpha 2 (COL1A2), collagen type 3 alpha 1 
(COL3A1), and hyaluronan synthase 2 (HAS2).  These ECM genes were targeted as 





2.3 Materials and Methods 
 
2.3.1 Peptide Synthesis 
All peptides were synthesized using a 0.4mmol scale Knorr-amide resin (Synbiosci 
Corp.) and standard FMOC (9-fluorenylmethyloxycarbonyl) chemistry.  Once 
synthesized peptides were capped with an acetyl group, they were then cleaved from 
the resin using 95% trifluoroacetic acid (Sigma-Aldrich), 2.5% water, 1.25% 
triisopropylsilane (Sigma-Aldrich), and 1.25% ethanedithiol (Sigma-Aldrich).  
Cleaved peptides were precipitated in cold ether and then recovered utilizing 
centrifugation.  The crude peptides were then further purified using an acetonitrile 
gradient on an AKTA Explorer FPLC (GE Healthcare) equipped with a 22/250 C18 
reversed phase column (Grace Davidson). Molecular weight and purity was 
confirmed by time of flight MALDI mass spectrometry using a 4800 Plus MALDI 






2.3.2 Substrate Modification 
NHS-ester PEG thin film coated glass slides, termed Nexterion H, were purchased 
from Schott.  These substrates once cut to 10x10mm were rinsed with 50mM sodium 
borate buffer pH 7.5.  They were then incubated, according to the literature,
[14]
 in 
varying concentrations of peptide resuspended in 50mM sodium borate buffer pH 7.5 
for ~21 hours with 300rpm shaking on a plate shaker at room temperature.  Post 
incubation substrates were dried with dry nitrogen gas and used immediately or stored 
at -20˚C. 
 
2.3.3 Cell Culture 
I-HVFFs were developed and provided to us by Dr. Susan Thibeault at the University 
of Wisconsin, Madison.
[15]
  These I-HVFFs were kept in an unscarred phenotypic 
state by growing them in Dulbecco’s Modified Eagles Medium (Sigma-Aldrich) 
supplemented with 10% FBS (Sigma-Aldrich), 1% penicillin/streptomycin (Sigma-
Aldrich), 1% MEM non-essential amino acids (Sigma-Aldrich), and 200ug geneticin 
(G418; Teknova) per mL of media.  Unscarred I-HVFFs were induced into a scarred 
phenotypic state by utilizing induction media.  This media contained all the same 
aforementioned media components except the 10% FBS was removed and 10ng/mL 
of transforming growth factor – beta 1 (TGF-β1; Biosource) was added.  Successful 








2.3.4 Peptide Functionality 
NHS-ester PEG thin film substrates modified with 0.1, 0.01, or 0.001mM of RGD or 
RGE were incubated with 20,000 I-HVFFs/mL in normal unscarred media for 4hrs at 
37˚C at 5% CO2.  Post-incubation all substrates were briefly rinsed in PBS pH 7.4 to 
dislodge any non-adhered I-HVFFs.  Ten random images of each substrate’s surface 
were then taken using a Nikon Eclipse TS100 optical microscope & digital camera.  
Finally, the number of I-HVFFs on the differently modified substrates was manually 
counted & then this quantitative data was analyzed using basic statistical software. 
 
2.3.5 Immunohistochemistry 
20,000 I-HVFFs/mL in normal unscarred media were incubated with NHS-ester PEG 
thin film substrates previously modified with 0.01 or 1mM RGD for 4hrs at 37˚C & 5% 
CO2.  All substrates were then briefly rinsed in PBS pH 7.4 to dislodge any non-
adhered I-HVFFs post incubation, and placed back in normal unscarred media until I-
HVFF confluency reached ~50%.  Once reached, half were rinsed and placed back in 
normal unscarred media while the other half were placed in the aforementioned 
induction media.  They were then allowed to grow/induce for 5 days in their 
respective media at 37˚C & 5% CO2 with a media change on day 2.  The cells were 
then fixed for 30 minutes in ~10% formaldehyde (Mallinckrodt Chemicals) and 
permeabilized with 0.5% Triton-X 100 (Sigma-Aldrich) for 20 minutes.  Blocking 
occurred in 3% bovine serum albumin (BSA; SeraCare Life Sciences) for 1hr at room 
temperature.  Next all substrates were incubated for 90 minutes at room temperature 






BSA + PBS pH 7.4.  Subsequently, substrates were incubated with 5ug/mL of 
AlexaFluor 488 goat anti-mouse secondary antibody (Invitrogen) in 2% BSA + PBS 
pH 7.4 for 45 minutes at room temperature.  Finally, after rinsing with 0.05% Tween 




NHS-ester PEG thin film substrates were modified in the same aforementioned 
fashion with 0.01, 0.1, or 1mM of RGD peptide.  Following modification I-HVFFs 
were grown on them using techniques described earlier.  Post growth, RNA was 
isolated from each sample utilizing the Nucleospin total RNA isolation kit (Clontech).  
Purified RNA was then quantified using a NanoDrop 2000 spectrophotometer 
(Thermo).  Reverse transcription of the pure RNA was achieved using a High-
Capacity cDNA reverse transcription kit (Life Technologies).  Finally, real-time or 
quantitative polymerase chain reaction (qPCR) was conducted utilizing an Applied 
Biosystems 7500 real-time PCR machine.  Briefly, qPCR reactions were set-up 
utilizing the TaqMan gene expression master mix (Life Technologies), six ECM 
gene-specific probes (Life Technologies) [Including human ELN, DCN, FN, 
COL1A2, COL3A1, and HAS2.], and template cDNA from the different samples.  
qPCR reaction conditions were as follows: 50˚C for 2min, 95˚C for 10min, and 40 
cycles of 95˚C for 15sec, and 60˚C for 1min.  Human β-actin was used as the 
endogenous control.  The average cycle threshold (Ct) of each sample was then used 






2.4 Results and Discussion 
Peptide and NHS-ester PEG thin film functionality was confirmed. Substrates 
modified with 0.1mM RGD had an average of ~35 I-HVFFs per mm
2
 adhered while 
0.001mM RGD had only an average of ~18 I-HVFFs per mm
2
 (Figure 2.1A).  
Furthermore, for each concentration of RGD and RGE more I-HVFFs per mm
2
 
adhered to the integrin-binding peptide, RGD, then the non-integrin binding control, 
RGE, peptide (Figure 2.1A).  Finally, the fewest number of I-HVFFs, at an average of 
~2 I-HVFFs per mm
2
, bound to unmodified control NHS-ester PEG thin film 
substrates (Figure 2.1A) confirming PEG’s anti-fouling capabilities.  These data 
overall suggest that the PEG, RGD, and RGE peptides all functioned according to the 
literature,
[14,16]
 and that I-HVFF binding mainly occurred through the RGD integrin 
binding site.  Immunohistochemistry confirmed that I-HVFFs grown in a healthy 
environment, without TGF-β1, were unscarred & did not express α-SMA (Figure 
2.1B).  While those growing in a scar-like environment, with TGF-β1, became 
myfibroblastic/scarred & expressed α-SMA (Figure 2.1D and 1E).
[17]
  Furthermore, 
increasing RGD concentration from 0.01mM (Figure 2.1D) to 1mM (Figure 2.1E) 










Figure 2.1 Peptide and NHS-ester PEG thin film functionality confirmed.  High 
concentrations of RGD, 0.1mM, bind more I-HVFFs then lower concentrations (A).  
PEG thin film has anti-fouling capabilities with unmodified control binding the 
lowest number of I-HVFFs per mm
2
 (A).  Immunohistochemical α-SMA staining 
verified unscarred I-HVFFs (B) were induced into a scarred myofibroblastic state (D 
& E).  Furthermore, I-HVFFs spread more readily on high 1mM RGD (E) versus low 
0.01mM RGD (D).  B = α-SMA stained unscarred I-HVFFs on 0.01mM RGD, C = 
brightfield image of unscarred I-HVFFs on 0.01mM RGD, D =  α-SMA stained TGF-
β1 scarred I-HVFFs on 0.01mM RGD, & E =  α-SMA stained TGF-β1 scarred I-
HVFFs on 1mM RGD.  Scale bars = 20um.  Treatments in A with non-matching 
symbols are statistically different from each other according to a one-way ANOVA + 






RGD concentration and fibroblast phenotype affected the expression of ECM genes.  
With respect to the control, no RGD unscarred I-HVFFs which was set equal to 1, 
changes in the I-HVFF growing environment caused a change in phenotype, from 
unscarred to scarred, resulting in up-regulated gene expression of all six ECM genes 
except DCN & HAS2 (Figure 2.2).  Variations in RGD integrin concentration 
impacted ECM gene expression only in specific phenotypes.  Unscarred I-HVFFs 
were unaffected by changes in RGD integrin concentration for all six ECM genes 
except HAS2 which saw down-regulation with addition of any RGD (Figure 2.2).  
Scarred I-HVFFs were affected, with ELN gene expression being up-regulated as the 
concentration of RGD increased (Figure 2.2).  Similar results, albeit of smaller 
magnitude were obtained for COL3A1 gene expression as well (Figure 2.2).  HAS2 
expression was also impacted with a further down regulation in its expression at the 
highest RGD concentration in scarred I-HVFFs (Figure 2.2).  DCN, FN, & COL1A2 
remained unchanged in scarred I-HVFFs with respect to changes in RGD 








Figure 2.2 Illustrates that varying both RGD concentration and cell phenotype, from 
unscar to scar, has various impacts on the expression of six ECM genes including 
elastin (ELN), collagen 3 alpha 1 (COL3A1), hyaluronan synthase 2 (HAS2), decorin 
(DCN), fibronectin (FN), collagen 1 alpha 2 (COL1A2).  Of note is the major impact 
scarring and varying RGD has on ELN & COL3A1 expression.  While the phenotype 
change from unscarred to scarred I-HVFFs results in up-regulation in all six ECM 
genes tested except for HAS2 & DCN.  A = 0.01mM RGD Unscar, B = 1mM RGD 
Unscar, C = No RGD Scar, D = 0.01mM RGD Scar, E = 0.1mM RGD Scar, F = 
1mM RGD Scar. Treatments within each ECM gene with non-matching symbols are 
statistically different from each other according to a one-way ANOVA + Tukey post-






In summary, our results demonstrate that RGD concentration and cell phenotype 
impact gene expression of the ECM genes investigated here. This suggests that 
controlling RGD concentration with respect to cell phenotype may improve a 
material’s bioactivity and thereby improve its regenerative properties when implanted 
in any type, vocal fold or otherwise, of damaged or scarred tissue.  Future work will 
focus on ascertaining if these changes in ECM gene expression also result in changes 
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CHAPTER 3. DEVELOPMENT AND CHARACTERIZATION OF A 
NANOPARTICLE SYSTEM THAT RESISTS LYOPHILIZATION BASED 
AGGREGATION, RESPONDS TO ENVIRONMENTAL STIMULI, AND CAN 
BE MODIFIED WITH TARGETING LIGANDS 
3.1 Abstract 
Poly(lactic-co-glycolic acid) (PLGA) is a popular material used to synthesize 
nanoparticles for drug delivery. However, PLGA nanoparticles lack desirable attributes 
including active targeting abilities, resistance to aggregation during lyophilization, and 
the ability to respond to dynamic environmental stimuli. To overcome these issues, we 
synthesized a nanoparticle consisting of a static PLGA core encapsulated within a 
dynamic shell of poly(N-isopropylacrylamide). Dynamic light scattering and 
transmission electron microscope imaging were used to characterize the nanoparticles, 
while an MTT assay and ELISA suggested biocompatibility in THP1 cells. Finally, a 
collagen type II binding assay showed successful modification of these nanoparticles 
with an active targeting moiety. 
 
3.2 Introduction 
Poly(lactic-co-glycolic acid) (PLGA) is a biocompatible, biodegradable synthetic 
polymer that is easy to fabricate into size-specific nanoparticles and has a well-
documented ability for sustained therapeutic release.
[1-3]
 Although many investigators and 






nanoparticles for use in research and commercial products.
[1, 3-5]
 PLGA nanoparticles still 
have significant limitations when it comes to using them to deliver therapeutics to a 
specific disease site. One such limitation is that PLGA nanoparticles, when delivered 
intravenously, have no active targeting capabilities and are restricted to passive targeting 
via the enhanced permeability and retention (EPR) effect seen in cancerous and inflamed 
tissues.
[6-8]
 Tissue accumulation via the EPR effect can provide potential benefits for 
cancer drug delivery,
[6]
 but it renders drug delivery for other disease states that lack the 
EPR effect problematic. Other investigators have attempted to overcome this challenge 
by modifying PLGA nanoparticles for “active” targeting with the addition of monoclonal 
antibodies.
[9]
 Another challenge is the long-term storage of aqueous suspensions of 
PLGA nanoparticle systems, due to hydrolytic degradation of the polymer and 
subsequent release of the encapsulated therapeutic.
[10, 11]
 To overcome this issue, 
researchers have used lyophilization to prepare therapeutic-containing PLGA 
nanoparticles for long-term storage.
[10, 11]
 However, this simple solution introduces 
another problem: lyophilization causes the PLGA nanoparticles to aggregate into clumps 
that upon rehydration, readily fall out of solution.
[10, 11]
 Finally, PLGA nanoparticles are 
limited in their responses to environmental stimuli like temperature or pH. Although 
environmental sensitivity is not a requirement for nanoparticle systems, it does provide 
advantages, such as the ability to control therapeutic release from nanoparticle carriers 




In an effort to overcome the limitations associated with PLGA nanoparticles, as well as 






within a shell of poly(N-isopropylacrylamide) (pNIPAM). pNIPAM was chosen because 
it is a versatile material with some inherently unique properties. The pNIPAM shell can 
be synthesized as a homopolymer, or as a copolymer with incorporation of a variety of 
chemical moieties with defined concentrations that can then be further modified with 
active targeting functional groups.
[13-15]
 Additionally, pNIPAM can tolerate 
lyophilization;
[16]
 we hypothesized that a pNIPAM shell would protect encapsulated 
PLGA nanoparticles from aggregation during lyophilization. Finally, pNIPAM is a 
temperature responsive polymer that can undergo a phase transition at a lower critical 
solution temperature (LCST) around 31-32°C.
[17]
 At temperatures below its LCST, 
pNIPAM nanoparticles are swollen and hydrophilic.
[13]
 However, once the temperature 
increases above the LCST, pNIPAM nanoparticles collapse as the polymer becomes 
hydrophobic.
[13]
 Thus, by encapsulating PLGA nanoparticles in a pNIPAM shell, the 
nanoparticles should have the ability to respond to environmental stimuli, such as 
temperature. This response could then be used for loading and/or controlling the release 
of therapeutics from the pNIPAM layer.
[18]
 Here, we characterize this novel PLGA core + 
pNIPAM shell nanoparticle system. 
 
3.3 Materials and Methods 
 
3.3.1 Core + Shell Nanoparticle Synthesis 
Synthesis of the core + shell nanoparticles occurred in two steps: synthesis of the PLGA 
cores followed by the addition of the pNIPAM shell (Figure 3.1). First, PLGA cores were 
synthesized using a single emulsion technique.
[26]






lactide/glycolide) 50:50 (PLGA; Polysciences Inc.) was dissolved in 5mL of 
dichloromethane (DCM; Sigma-Aldrich), added to 20mL of 5% polyvinyl alcohol (PVA; 
Alfa Aesar; Avg. MW = 11,000 – 31,000), and homogenized for 30s using a probe 
sonicator (Branson Sonifier 450) to generate a single emulsion. The emulsion was then 
added to 100mL of rapidly stirred distilled water and left overnight to allow for full 
evaporation of the DCM. The PLGA nanoparticles were further purified via 
centrifugation washes with distilled water. Any clumps of PLGA nanoparticles that 
remained after centrifugation were disrupted using brief sonication. The PLGA cores 
were then encapsulated in pNIPAM shells using aqueous free radical precipitation 
polymerization under a nitrogen atmosphere.
[27-29]
 Briefly, 0.27g N-isopropylacrylamide 
[2.385mmol] (Polysciences Inc.), 0.021g N-N’-methylene bisacrylamide [0.136mmol] 
(Fluka), 0.012g sodium dodecyl sulfate [0.042mmol] (Sigma Aldrich), and 0.015g 
ammonium persulfate [0.066mmol] (Sigma Aldrich) were dissolved in 30mL of distilled 
water and purged of oxygen by nitrogen bubbling. For nanoparticle targeting, either 
1.67µL [0.024mmol or 1 mol%] or 8.35 µL [0.121mmol or 5 mol%] of acrylic acid (AAc; 
Alfa Aesar) were included. Meanwhile, 20mL of the PLGA nanoparticle cores were 
added to a 250mL three-neck round bottom flask and equilibrated to 70°C for 20 minutes 
under nitrogen with stirring. Then, 10mL of the shell solution was added to the 70°C 
equilibrated PLGA nanoparticle cores and allowed to polymerize. Additional 5mL 
aliquots of shell solution were added 30, 50, 70, and 90 minutes after the initial 
polymerization. Polymerization continued for 6 hours after the final addition of shell 
solution. Purification was achieved through dialysis of the PLGA core + pNIPAM shell 






(Spectrum Laboratories, Inc.). Then centrifugation washes were performed in order to 
further isolate the core + shell nanoparticles. Any clumps of core + shell nanoparticles 
post centrifugation were dispersed using brief sonication. Finally, a portion of the 
samples were lyophilized and then rehydrated in distilled water. 
 
3.3.2 Transmission Electron Microscopy (TEM) Characterization 
Images were taken of the pre- and post- lyophilized nanoparticle samples stained with 2% 
uranyl acetate. The stained nanoparticles were then placed on a glow-discharged 400 
mesh coated with formvar + carbon film, and then placed in a Philips CM-100 TEM 
where images were captured on Kodak SO-163 electron image film. 
 
3.3.3 Nanoparticle Sizing and Zeta Potential 
Measurements were taken with a Malvern Zetasizer Nano ZS90. Pre- and post-
lyophilized nanoparticles were suspended in distilled water and analyzed for particle size 
in polystyrene cuvettes at 25°C and 37°C. Temperature sweeps were performed by 
varying temperature from 20°C to 50°C to 20°C in 1° increments with measurement of 
particle size with each change in degree. Disposable Malvern ζ-potential cuvettes were 
used to acquire ζ-potential measurements at 25°C and 37°C. Note after making any 
change in temperature, nanoparticle samples were allowed to equilibrate for five minutes 







3.3.4 Peptide Synthesis and Purification 
The collagen type II binding peptide single amino acid sequence consisting of 
WYRGRLGC was identified from the literature.
[24]
 It was synthesized at a 0.4mmol scale 
on Knorr-amide resin (Synbiosci Corp.) using standard FMOC (9-
fluorenylmethyloxycarbonyl) chemistry. Two different chemistries were used to couple 
each amino acid (Synbiosci Corp). The first coupling reagents consisted of N-
hydroxybenzotriazole (HOBt; Synbiosci) and N,N’ diisopropylcarbodiimide (DIC; 
Sigma-Aldrich) and the second coupling reagents were O-Benzotriazole-N,N,N’,N’-
tetramethyl-uronium-hexafluoro-phosphate (HBTU; Synbiosci) and lutidine (Sigma-
Aldrich). Following synthesis, the peptide was cleaved from the resin with 95% 
trifluoroacetic acid (Sigma-Aldrich), 2.5% water, 1.25% triisopropylsilane (Sigma-
Aldrich), and 1.25% ethanedithiol (Sigma-Aldrich), precipitated in cold ether, and 
recovered by centrifugation. It was then purified with an acetonitrile gradient on an 
AKTA Explorer FPLC (GE Healthcare) equipped with a 22/250 C18 reversed phase 
column (Grace Davidson). Molecular weight was confirmed by time of flight MALDI 
mass spectrometry using a 4800 Plus MALDI TOF/TOF Analyzer (Applied Biosystems). 
Theoretical molecular weight of WYRGRLGC was calculated to be 1009.1 while the 
actual molecular weight was found to be 1009.58. A biotinylated version of the peptide 
(biotin-WYRGRLC) was purchased from Genscript and its theoretical molecular weight 







3.3.5 Modifying Core + Shell Nanoparticle with Targeting Moiety 
Nanoparticle targeting was achieved through the addition of a collagen type II binding 
peptide to the AAc groups on our core + shell nanoparticles using a heterobifunctional 
crosslinker (Figure 3.1). Briefly, 0.4mg of 1-ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride (EDC; Thermo-Scientific) and 1.1mg 
of N-hydroxylsulfosuccinimide (sulfo-NHS; Thermo-Scientific) were added to 1mg of 
core + shell nanoparticles for 15 minutes in activation buffer (0.1M 2-(N-
morpholino)ethanesulfonic acid (MES; Amresco, pH 6.0). Excess EDC and sulfo-NHS 
was removed by a centrifuge wash. The heterobifunctional crosslinker, N-[β-
maleimidopropionic acid] hydrazide (BMPH; Thermo-Scientific) was added to the 
activated nanoparticles (0.1mg for 1 mol% AAc nanoparticles or 0.3mg for 5 mol% AAc 
nanoparticles) for 2 hours in coupling buffer (0.1M MES, pH 7.2). Excess BMPH was 
removed using gel filtration chromatography through an ÄKTA Purifier FPLC (GE 
Healthcare) with Bio-Scale Mini Bio-Gel columns packed with polyacrylamide beads 
(Bio-Rad Laboratories). The collagen type II binding peptide (15% biotinylated) was 
added to the nanoparticles for 2 hours in coupling buffer. Excess peptide was removed 
via gel filtration chromatography. Confirmation of peptide addition was performed using 
a flouraldehyde assay (Pierce), which reacts with free amines, and a streptavidin color 
development assay, which confirmed the presence of the biotinylated peptide on the 







3.3.6 Collagen Type II Binding Assay 
Modified nanoparticles were tested for their ability to bind to collagen type II. A 96-well 
plate (Greiner) was coated with collagen type II from chicken sternum (Sigma) in 0.25% 
acetic acid at a concentration of 0.5mg/ml overnight. Following three washes, the plate 
was blocked with 1% bovine serum albumin (BSA; SeraCare Life Systems) for 1 hour. 
After three more washes, the collagen type II binding peptide modified core + shell 
nanoparticles and unmodified controls were incubated in the collagen type II coated plate 
for 1 hour. Following three more washes, streptavidin (R&D Systems) was diluted 200X 
in 1% BSA and incubated for 20 minutes in the plate. After more washing to remove 
unbound streptavidin, a color solution (R&D Systems) was added for 20 minutes. 
Sulfuric acid (Mallinckrodt Chemicals) was then used to stop the reaction and absorbance 
was read at 450nm with a correction at 540nm. 
 
3.3.7 Cell Culture 
Immortalized human monocytes (THP1, ATCC) were grown in RPMI 1640 with L-
glutamine (Mediatech Inc) supplemented with 0.05mM mercaptoethanol (Sigma-Aldrich), 
10mM HEPES (Mediatech Inc), 1mM sodium pyruvate (Mediatech Inc), 10% fetal 
bovine serum (Hyclone), and 1% penicillin/streptomycin (Mediatech Inc). Cells were 








3.3.8 Nanoparticle Biocompatibility 
The biocompatibility of the nanoparticles was assessed by measuring toxicity and 
inflammation in THP1 cells. Cells were seeded at a density of 250,000 cells/mL in 96-
well plates (Corning) and treated with 10ng/mL phorbol 12-myristate 13-acetate (PMA, 
Sigma-Aldrich) for 48 hours to induce differentiation, which was confirmed by the 
monocytes becoming adherent. Following a change of media, cells were treated with 
various concentrations of core + shell nanoparticles. Control samples received PBS 
(negative control) or 50ng/mL lipopolysaccharide (LPS, Sigma-Aldrich) (positive 
control). After 24 hours, the media was collected for cytokine analysis and an MTT-
based assay was performed to determine cell toxicity using the Aqueous One 
Proliferation Kit (Promega) according to manufacturer’s instructions. Briefly, 20µL of 
reagent was added directly to 100µL of cells and media. After two hours of incubation in 
the cell culture incubator, the absorbance was read at 490nm with a correction at 650nm. 
 
The ability of the particles to cause an inflammatory response was determined by running 
conditioned cell media on a TNF-α ELISA (PeproTech) according to manufacturer 
instructions. Briefly, Nunc MaxiSorp 96-well plates were coated with capture antibody 
overnight. After blocking for one hour with 1% bovine serum albumin (Sera Lifesciences) 
in PBS, samples and standards were incubated for two hours with gentle rotation. 
Following incubation with a detection antibody and an avidin-horse radish peroxidase 
conjugate, the samples were developed with the addition of 2,2'-azino-bis(3-
ethylbenzthiazoline-6-sulphonic acid) (ABTS) liquid substrate (Sigma-Aldrich) and 






3.3.9 Statistical Analysis 
Data was analyzed for differences using a single factor ANOVA with a Tukey post-hoc 
test. A value of α = 0.05 was used for all analyses. Graphs are depicted as mean ± 
standard deviation. 
 
3.4 Results and Discussion 
 
3.4.1 Physical Characterization of the Core + Shell Nanoparticles 
Synthesis of the core + shell nanoparticles occurred in two steps: synthesis of the PLGA 
cores followed by the addition of the pNIPAM shell (Figure 3.1). Verification of 
successful encapsulation of the PLGA cores with the pNIPAM shells was initially 
achieved using dynamic light scattering to measure the size of the nanoparticles before 
and after the addition of the shell to determine the change in nanoparticle diameter. The 
diameter of the core + shell nanoparticles (Table 3.1) increased post addition of the 
pNIPAM shell, suggesting successful encapsulation. pNIPAM shell thickness ranged 
from ~100nm to ~200nm at 25°C, where an increase in shell thickness corresponded to 
an increase in the mole percent of acrylic acid, and therefore charge density. This 









Figure 3.1 Schematic of the synthesis of PLGA core + pNIPAM shell nanoparticles (A 
and B) and the subsequent chemistry (C) used to append the collagen type II binding 
peptide targeting ligand. 
 
Additional verification of successful encapsulation of the pNIPAM shell was provided by 
confirming a phase transition when the temperature was raised above its LCST. Because 
pNIPAM is a temperature sensitive polymer, we expected to see a difference in 
nanoparticle size, with the nanoparticle diameter being smaller at 37°C (above pNIPAM 
LCST) compared to 25°C (below pNIPAM LCST). All core + shell nanoparticles showed 
reduced diameters at 37°C compared to 25°C (Table 3.1). This trend is most pronounced 
with shell thicknesses that at 37°C range only from ~10nm to ~100nm with an increase in 
shell thickness again corresponding to an increase in the mole percent of acrylic acid 






Table 3.1 Characterization of Various Nanoparticle Samples 
















PLGA Core No 
25 392.3±13.9 -32.1±2.0 
NA 
37 377.2±20.2 -22.5±3.4 
      
PLGA Core + 
pNIPAM Shell 0 
mol% AAc 
No 
25 605.3±10.8 -28.3±4.4 106.5±5.4 
37 403.8±7.1 -25.0±2.5 13.3±3.6 
Yes 
25 610.2±14.2 -32.1±0.9 109.0±7.1 
37 414.5±7.9 -24.3±1.8 18.6±3.9 
      
PLGA Core + 
pNIPAM Shell 1 
mol% AAc 
No 
25 659.1±6.7 -28.0±6.0 133.4±3.4 
37 428.0±9.5 -22.7±2.7 25.4±4.7 
Yes 
25 681.7±20.9 -30.8±5.1 144.7±10.4 
37 447.0±13.5 -20.5±0.7 34.9±6.8 
      
PLGA Core + 
pNIPAM Shell 5 
mol% AAc 
No 
25 748.5±17.1 -34.9±2.5 178.1±8.5 
37 534.1±14.8 -25.1±3.1 78.4±7.4 
Yes 
25 818.3±3.9 -34.6±0.2 213.0±2.0 
37 575.9±16.6 -25.2±2.1 99.4±8.3 
a
 pH of all samples was between 5 and 6. 
b
 Determined by subtracting corresponding core from core+shell sample & dividing by 2. 
 
To assess colloidal stability of our core + shell nanoparticles above and below the phase 
transition temperature, we measured their ζ –potentials. According to the literature, 
nanoparticle ζ –potentials above 30mV or below -30mV are considered stable.
[20]
 As 
shown in Table 3.1, all nanoparticles, are near -30mV indicating that they are stable. 
 
3.4.2 Effects of Lyophilization on Core + Shell Nanoparticles 
Lyophilization is an effective way to prevent the release of therapeutics loaded into 
PLGA nanoparticles during long-term storage.
[10, 11]
 However, if not performed correctly, 






resolubilization of the clumped nanoparticles (Figure 3.2).
[10, 11]
 We used TEM imaging 
to visually confirm that well-defined spherical PLGA and PLGA core + pNIPAM shell 
nanoparticles were successfully synthesized pre-lyophilization (Figure 3.2). However, as 
also observed by others,
[10, 11]
 TEM imaging showed that lyophilization caused the PLGA 
nanoparticles to form aggregates (Figure 3.2). This aggregation resulted in an inability to 
measure diameter and ζ–potential of post-lyophilized PLGA nanoparticles. In contrast, 
encapsulation of PLGA nanoparticles with pNIPAM shells prevented aggregation of the 
PLGA nanoparticles following lyophilization, further confirming that the pNIPAM shell 
fully encapsulated the PLGA core. Additionally, we found that lyophilization of the core 








Figure 3.2 Transmission electron microscope images of the various nanoparticles both 
pre- and post-lyophilization. Scale bars = 250nm. 
 
3.4.3 Responses of C+S nPs to Dynamic Environmental Stimuli 
To further assess the response of our core + shell nanoparticles to temperature-based 
environmental stimuli, we used dynamic light scattering to measure the diameter of our 
core + shell nanoparticles as they were exposed to a dynamic range of temperatures from 
20°C to 50°C to 20°C. We found that the core + shell nanoparticles readily respond 
within this temperature range with all core + shell nanoparticle types decreasing in 






reversible, as the nanoparticles returned to their original diameter when the temperature 
was lowered back below their LCST. Additionally, the LCST of the pNIPAM shell was 
tuned by modifying the amount of acrylic acid that was incorporated as a co-monomer. 
As more acrylic acid was incorporated, the LCST of pNIPAM increased (Figure 3.3). The 
core + shell nanoparticles with 0 mol% acrylic acid exhibited an LCST at ~31-32°C, 
while the 1 mol% acrylic acid had an LCST at ~33-34°C, and the core + shell 
nanoparticles with 5 mol% acrylic acid had an LCST at ~35°C (Figure 3.3). This trend 
has previously been established in the literature.
[19, 21]
 In the future, these core + shell 
nanoparticles could be engineered to respond to different environmentally based stimuli 









Figure 3.3 Temperature sweeps of the various nanoparticles. Data is represented as mean 
± standard deviation (n=3). C = PLGA core only; C+S #% = PLGA core + pNIPAM shell 
+ mol% acrylic acid; L = Lyophilized. 
 
3.4.4 Core + Shell Nanoparticle Biocompatibility 
The biocompatibility of the core + shell nanoparticles was assessed by evaluating the 
toxicity and inflammatory response in an immortalized human monocyte cell line. This 
cell line was chosen because, in our experience, it shows increased sensitivity to toxicity 
compared to other cell lines. Additionally, monocytes have a significant role in the 
perpetuation of osteo- and rheumatoid arthritis,
[22, 23]
 an inflammatory disease model that 






therapeutics in the future. The core + shell nanoparticles were not toxic at any of the 
concentrations tested, as we saw no significant reduction in THP1 cell number (Figure 
3.4). However, the core + shell nanoparticles with 5 mol% acrylic acid induced a 
significant increase in proliferation of the THP1 cells at concentrations of 2.5 and 
5mg/mL compared to all other treatments (p<0.05; One-way ANOVA + Tukey post-hoc 
test). Next, the ability of the core + shell nanoparticles to elicit an inflammatory response 
was determined by measuring TNF-α production by THP1 cells using an ELISA. A 
significant inflammatory response, characterized by an increase in TNF-α production, is 
not desirable and would indicate non-biocompatibility. Similar to the PBS control, the 
core + shell nanoparticles did not elicit TNF-α production (Figure 3.5; p>0.05; One-way 
ANOVA + Tukey post-hoc test), suggesting these nanoparticles are biocompatible 
though further testing will be conducted in the future to verify this preliminary work. The 









Figure 3.4 Toxicity of the core + shell nanoparticles in human monocytes. φ represents 
p<0.05 compared to all other treatments (One-way ANOVA +Tukey post-hoc test). Data 
is presented as mean ± standard deviation (n=4). 
 
 
Figure 3.5 TNF-α production by human monocytes treated with core + shell nanoparticles. 
φ represents statistical significance from all other data points (p<0.05, One-way ANOVA 






3.4.5 Targeting Core + Shell Nanoparticles 
In order to increase the targeting capabilities of our core + shell nanoparticles beyond the 
passive EPR effect,
[6, 7]
 we modified them with a model active targeting moiety – a 
peptide that binds collagen type II (Figure 3.1).
[24]
 This model targeting moiety could be 
used to deliver therapeutics in an arthritic-based disease model seeing as collagen type II 
is readily found in the cartilage of the joints.
[25]
 However, this chemistry could easily be 
applied to attach other targeting moieties that contain a free thiol functional group.  
 
To assess whether incorporation of the collagen type II binding peptide allowed the core 
+ shell nanoparticles to bind to collagen type II, we utilized a microplate assay. This 
assay involved coating a 96-well plate with collagen type II, incubating it with collagen 
type II targeting enabled core + shell nanoparticles, and then probing for the presence of 
the biotin labeled collagen type II peptide. The results from this assay indicate that core + 
shell nanoparticles modified with collagen type II binding peptide bound collagen type II 
as compared to unmodified core + shell nanoparticle controls (Figure 3.6; p<0.05, One-
way ANOVA + Tukey post hoc test). Furthermore, the number of collagen type II 
binding peptide modified core + shell nanoparticles able to bind to collagen type II was 








Figure 3.6 Collagen type II binding assay for core + shell nanoparticles. 1% & 5% AAc 
modified NPs are statistically significant from each other and the controls as indicated by 
the different Greek letters (p<0.05; One-way ANOVA + Tukey Post-hoc test). Data 
presented as mean ± standard deviation (n=4). 
 
3.5 Conclusions 
In closing, we successfully encapsulated static PLGA core nanoparticles with a dynamic 
pNIPAM shell. The addition of this pNIPAM shell conferred many benefits including the 
ability to protect the PLGA cores from aggregating during lyophilization, the ability to 
modify the nanoparticles with active targeting moieties in a concentration-dependent 
manner, and the ability to change size based on external environmental-based stimuli. 
These core + shell nanoparticles are non-toxic and do not illicit inflammation in THP1 
cells suggesting biocompatibility. All of these abilities will prove important in future in 
vivo studies focused on examining the ability of these nanoparticles to deliver 
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CHAPTER 4. CONTROLLED RELEASE OF A CORTICOSTEROID FROM 
HYDROGEL TEMPLATED PLGA MICROPARTICLES FOR USE IN 
TREATING VOCAL FOLD SCARRING 
4.1 Abstract 
Vocal fold scarring is caused by improper regeneration of the extracellular matrix (ECM) 
post injury resulting in impaired phonation.  Alas, current treatments for vocal fold 
scarring only relieve the effects of the scar on phonation in the short term.  Long-term 
solutions, however, remain elusive.  Researchers have developed therapeutics to help 
treat vocal fold scarring, but barriers to the efficacy of these agents remain.  What is 
needed is an effective means by which to control administration of said therapeutics over 
the long term.  We looked to address this issue by loading dexamethasone (dM), an anti-
fibrotic and anti-inflammatory therapeutic, into a poly-lactic-co-glycolic acid (PLGA) 
microparticle (mP) delivery vehicle.  Release studies showed successful loading and 
release profiles of dM from three types of PLGA microparticles whose polymer chain 
terminating moiety, acid or ester, and molecular weight, low or high, were varied.  Acid 
low molecular weight PLGA mPs released ~100% dM the fastest at ~48hrs.  Ester low 
molecular weight PLGA mPs were slightly slower at ~72hrs while ester high molecular 
weight PLGA mPs only released ~40% dM by the conclusion of the study.  To ascertain 
dM’s anti-fibrotic and anti-inflammatory effectiveness when released from PLGA mPs 






Real-time PCR showed a marked down regulation in COL3A1 & COL1A2 in scarred 
fibroblasts treated with dM loaded mPs only, indicating dM maintained its anti-fibrotic 
activity over the long term.  While ELISAs illustrated that of the four pro-inflammatory 
cytokines tested dM’s anti-inflammatory affects over the long term were only maintained 
for one, interleukin-6.  Further work needs to be done, but our data show initial promise 
in using a PLGA microparticle based delivery system to control the release of a 
therapeutic relevant in the treatment of vocal fold scarring over the long term. 
 
4.2 Introduction 
Vocal fold scarring is an affliction that results in the formation of a disorganized and stiff 
ECM with abnormal ECM component densities & structures, including a significant 
increase in collagen deposition.
[1-3]
  It is caused by improper healing post injury and 
results in profound changes in the biomechanical properties of the vocal folds.
[3]
  Thereby, 
impairing their ability to generate a normal mucosal wave during phonation.
[3]
 
Finding an effective treatment for vocal fold scarring has been challenging.  Currently, 
treatments seek temporary solutions that correct glottal incompetence and reduce stiffness 
caused by the scar through the augmentation of the vocal folds using various injectable 
materials, such as hyaluronic acid or calcium hydroxylapatite.
[4,5]
  Unfortunately,  these 
solutions do not treat the actual scar, but only relieve its effects over the short term seeing 




To solve this problem researchers have been testing the impact various therapeutics have 






the one used in this study, is the corticosteroid dM which has shown significant anti-
fibrotic, in its suppression of collagen production, and anti-inflammatory attributes.
[6,7]
  
However, realizing the full potential of such a therapeutic has not been fully achieved due 
to many barriers, including the fact that these therapeutics are usually most effective 
when delivered directly to the site of scarring.
[6]
  This can be problematic seeing as, 
although one can inject them directly into scarred vocal folds, they usually are cleared in 
a short period of time.  This necessitates the need to re-inject the therapeutic multiple 
times in order to maintain its efficacy.  Though this is possible, issues of patient safety 
and tolerance quickly become significant problems one must deal with if one were to 
pursue such a rigorous treatment method. 
 
Here we seek to address both prolonging the residency of dM within a target area in 
addition to showing that this therapeutic will remain effective over the long term.  To 
achieve this, a delivery system was used in which dM was loaded into mPs composed of 
PLGA.  This polymer was chosen due to several beneficial attributes including its high 
biocompatibility, approval for use in humans by the US Food and Drug Administration, 
and proven ability at loading and releasing many different types of therapeutics.
[8-11]
  To 
guarantee the controlled delivery of an effective therapeutic dose we sought to synthesize 
micron sized particles whose larger size would allow more drug to be loaded and 
subsequently released over the long term.  These dM-loaded microparticles were 
synthesized using a hydrogel template based method that yields a highly uniform 
production of microparticles.
[12]
  A release study was done to elucidate the release profile 






data, dM loaded ester terminated LMW PLGA microparticles were selected and a long-
term dM release effectiveness study was conducted on scarred immortalized human vocal 
fold fibroblasts (I-HVFFs).  Long-term dM effectiveness was verified using real-time or 
quantitative PCR (qPCR) to ascertain collagen gene expression.  Pro-inflammatory 





4.3 Materials and Methods 
 
4.3.1 Microparticle Fabrication 
Microparticles used here were synthesized using a hydrogel template method described in 
detail in the work by Acharya, et al.
[12]
  Briefly, a polydimethylsiloxane (PDMS) template 
was generated from a pre-fabricated silicon wafer with circular posts 50um in diameter 
and 30um in height.  The patterned side of this PDMS template was then covered in a 
thin film of clear melted (50-55°C) porcine gelatin (30% w/v; Sigma-Aldrich) and then 
allowed to cool at 4°C for 5 min.  Post cooling the gelatin solidified and was gently 
peeled away from the PDMS template resulting in the formation of a 50um in diameter 
by 30um deep welled gelatin template. 
 
Wells of this gelatin template were then filled with a 9:1 dichloromethane (Sigma-
Aldrich) to methanol (Sigma-Aldrich) solution in which 1% w/v dexamethasone (dM; 
Alfa-Aesar) and either 40% w/v low molecular weight (LMW; ~6700Da) acid terminated 






PLGA (Lactel), or 10% w/v high molecular weight (HMW; ~111,500Da) ester 
terminated PLGA (Lactel) had been dissolved.  This was achieved by transferring 50uL 
of one of the dM + PLGA solutions to the patterned surface and then evenly spreading it 
over the entire gelatin template using a razor blade.  The solvents were then left to 
evaporate at room temperature for 5-10min.  Each template underwent three 50uL swipes 
with one of the dM + PLGA solutions. 
 
The filled gelatin templates were then dissolved using 60°C deionized water in order to 
melt the gelatin thereby releasing the dM + PLGA microparticles into solution.  The dM 
+ PLGA microparticles were then separated from the gelatin utilizing centrifugation 
based washing.  Briefly, the microparticles were pelleted at 4000g for 5min.  The melted 
gelatin solution was then removed and fresh deionized water was added and the pelleted 
dM + PLGA microparticles were resuspended in it.  This constituted one wash.  Overall, 
the dM + PLGA microparticles were washed three to four times.  After the final wash, the 
dM + PLGA microparticles were pelleted and the supernatant was removed.  The pelleted 
dM + PLGA microparticles were then dried for 12-24hrs in a lyophilizer, and finally 
stored at -20°C for later use. 
 
4.3.2 Dexamethasone Release Study 
Into low-bind Eppendorf tubes 2mg of one of the three different types of PLGA 
microparticles, either dM loaded or not, were weighted out to give each an N=3.  Next 
100uL of PBS pH 7.2 was added to each tube and then all tubes were placed on an orbital 






4000g for 5min.  The supernatant was then completely removed and stored in a fresh 
labeled tube for each sample.  Next, the pelleted microparticles were resuspended in 
100uL of fresh PBS pH 7.2.  Finally, the tubes were put back on the orbital shaker at 
400rpm at 37°C until the next time point was reached at which point this procedure was 
repeated. 
 
The absorbance at 240nm, the peak absorbance of dM, was read for all samples at every 
time point.  This data was then compared to a dM + PBS pH 7.2 standard curve in order 
to ascertain the concentration of dM in each sample.  Finally, percent cumulative dM 
release was determined by comparing the amount of dM released from each PLGA type 
over time to the total amount of dM loaded in 2mg of fresh dM loaded PLGA 
microparticles of that corresponding PLGA type. 
 
4.3.3 Cell Culture 
An immortalized human vocal fold fibroblast (I-HVFF) cell line was obtained from Dr. 
Susan Thibeault from the University of Wisconsin, Madison.
[14]
  These I-HVFFs were 
grown in a normal unscarred state in Dulbecco’s Modified Eagles Medium (Sigma-
Aldrich) supplemented with 10% FBS (Sigma-Aldrich), 1% penicillin/streptomycin 
(Sigma-Aldrich), 1% MEM non-essential amino acids (Sigma-Aldrich), and 200ug 
geneticin (G418; Teknova) per mL of media.  Unscarred I-HVFFs were induced into a 
scarred phenotypic state by changing to an induction media.  This induction media 
includes all of the same aforementioned components of unscarred media except FBS.  It 







I-HVFFs were initially seeded at 2000 cells/well in a 96-well plate and left to attach 
overnight at 37°C and 5% CO2.  Then all wells were rinsed with 200uL of Dulbecco’s 
PBS pH 7.4.  Next a set of control wells were left unscarred while the rest were induced 
into a scarred phenotype by incubating them for 48hrs at 37°C and 5% CO2 in induction 
media.  Post scarring wells were rinsed with Dulbecco’s PBS pH 7.4 again and then 
either exposed to normal unscarred media, induction media + no dM, induction media + 
50ng/mL free dM, induction media + 0.01mg per well dM loaded mPs, or induction 
media + 0.01mg per well PLGA no dM mPs.  These various solutions were left on the I-
HVFFs for 24hrs at 37°C and 5% CO2.  After this time had elapsed, the cells were spun 
at 2000g for 10min to remove the mPs from suspension in the media solutions as a way 
to mimic in vivo entrapment in tissue.  The supernatants from each well were then 
removed to mimic the clearance of drug as seen in in vivo systems, and fresh either 
unscarred media for the control wells or scarred induction media for all other wells was 
added.  The I-HVFFs were then left to grow at 37°C and 5% CO2 for 72hrs more. 
 
At this point the media was removed and saved for later pro-inflammatory cytokine 
analysis, while the RNA was purified from the fibroblasts in each of the different I-HVFF 
treatment samples using a Nucleospin total RNA isolation kit (Clontech).  Once purified 
the RNA yield was quantified using a NanoDrop 2000 spectrophotometer (Thermo).  
Next the RNA was reverse transcribed into cDNA using the High-Capacity cDNA 
reverse transcription kit (Life Technologies).  Real-time or quantitative PCR reactions 






combined with three gene-specific probes (Life Technologies) including β-actin, 
COL1A2, or COL3A1 and template cDNA from the different samples.  These reactions 
were then run on an Applied Biosystems 7500 real-time PCR machine under the 
following conditions:  50°C for 2min, 95°C for 10min, and 40 cycles of 95°C for 15sec, 
and 60°C for 1min.  The endogenous control was human β-actin.  Average cycle 
threshold (Ct) from each sample was then used for the calculation of COL1A2 or 
COL3A1 expression levels using the relative comparative Ct method. 
 
4.3.5 Cytokine Analysis 
Four human pro-inflammatory cytokines were analyzed including interferon-gamma, IL-
1beta, IL-6, and TNF-alpha utilizing a sandwich electrochemiluminescent based ELISA.   
To start a multi-spot human cytokine tissue culture assay kit was purchased from Meso 
Scale Discovery (MSD).  The kit contained a 96-well 4 spot human proinflammatory-4 I 
plate pre-coated with capture antibodies to the aforementioned cytokines.  The analysis 
was conducted according to company instructions.  Briefly, wells were blocked with 1% 
w/v Blocker B in PBS pH 7.2 for 1hr.  Wells were then washed 3 times with PBS + 0.05% 
Tween20.  Next either 25uL of standards or samples were added to each well, and the 
plate was sealed and vigorously shaken for 2hrs at 700rpm at room temperature.  
Addition of 25uL of detection antibody solution was then immediately added and the 
plate was resealed and shook at 700rpm at room temperature for 2hrs.  Finally, the wells 
were washed 3 times with PBS pH 7.2 + 0.05% Tween20 and then 2x Read Buffer T was 







4.4 Results and Discussion 
Production of the dM loaded microparticles using three different PLGAs including acid 
terminated LMW, ester terminated LMW, and ester terminated HMW microparticles was 
successful using the hydrogel template based method.
[12]
  All three types of PLGA 
yielded the same relatively uniform microparticle structure as shown in Figure 4.1. 
 
 
Figure 4.1 Example images of fluorescein loaded hydrogel templated 50um x 30um ester 
terminated LMW PLGA microparticles.  A = brightfield image, B = fluorescent image.  
Scale bars = 50 um. 
 
A 168hr or 7 day release study was then conducted in order to ascertain the release 
profiles of the dM from the various types of PLGA microparticles (Figure 4.2).  An initial 
12hr burst release of dM was observed with all three types of PLGA.  The release profiles 






microparticles releasing most of their dM pay load by the 48hr mark (Figure 4.2).  The 
ester terminated LMW PLGA microparticles took slightly longer with most dM released 
within 72hrs (Figure 4.2).  The ester terminated HMW PLGA microparticles on the other 
hand released dM at a much slower rate post burst release with only about 40% of the 
loaded dM released by the end of the 168-hour study (Figure 4.2).  Based on this data, 
dM loaded ester LMW microparticles were chosen for our long-term cell studies as they 
gave the most desirable long-term dM release profile.  Furthermore, this data agreed with 
the literature in that our acid terminated PLGA microparticles released dM slightly faster 
than our corresponding ester terminated PLGA microparticles of the same MW.
[15]
  Our 
LMW PLGA released dM significantly faster than the HMW PLGA with the same 










Figure 4.2 Comparative release profiles of percent cumulative dexamethasone (dM) 
release over a 168-hour or 7-day period of time from acid LMW, ester LMW, or ester 
HMW PLGA microparticles. 
 
To assess the maintenance of dM’s anti-fibrotic effects over the long term in scarred I-
HVFFs, we used qPCR and looked at its impact on collagen gene expression, specifically 
COL1A2 & COL3A1 genes.  The literature has shown that collagen gene expression is 
up-regulated in vocal fold scarring due in part to the presence of TGF-β1.
[3,16, 17]
  We 
sought to model vocal fold scarring in vitro by exposing I-HVFFs to exogenous TGF-β1 






success and a ~2.5-fold increase was seen in COL1A2 and ~3.5-fold increase for 
COL3A1 was observed in our scarred I-HVFFs versus unscarred I-HVFFs.  Upon 
administering both free dM and dM loaded ester terminated microparticles to our scarred 
I-HVFFs we saw a marked decrease in COL1A2 and COL3A1 expression (data not 
shown) early on confirming what had been seen in the literature.
[7]
  However, by the end 
of the long-term study at day 4 free dM no longer maintained its anti-fibrotic efficacy as 
COL1A2 and COL3A1 expression returned to normal scar levels (Figure 4.3).  
Meanwhile, dM loaded ester terminated PLGA microparticles at day 4 maintained dM’s 
anti-fibrotic efficacy by continuing to depress COL1A2 and COL3A1 expression levels 
(Figure 4.3).  Note we also observed that PLGA only microparticles did not elicit a pro-
fibrotic response.  Instead, it seems they elicit an anti-fibrotic behavior in scarred I-








Figure 4.3 Illustrates that dexamethasone (dM) effectively knocks down COL1A2 and 
COL3A1 gene expression over the long term only in scarred immortalized human vocal 
fold fibroblasts exposed to dM loaded mPs.  Those treatments within each collagen type 
with non-matching symbols are statistically different from each other according to a one-
way ANOVA + Tukey post-hoc test; p < 0.05. 
 
Finally, we sought to investigate the impact dM had on affecting the inflammatory 
responses of our I-HVFFs.  Inflammation plays a major role in the formation of a scar 
with fibroblasts playing a role in this process.
[13, 18]
  Using our in vitro vocal fold 
fibroblast scar model we sought to ascertain whether or not dM’s anti-inflammatory 
capabilities would remain effective over the long term.  To assess the inflammatory 






including interferon-gamma (IFN-g), interleukin-1β (IL-1b), interleukin-6 (IL-6), and 
tumor necrosis factor-α (TNF-a), using a sandwich electrochemiluminescent based 
ELISA.  We found unscarred I-HVFFs released the following levels of all four cytokines; 
~110pg/mL for IL-6 (Figure 4.4), ~0.5pg/mL for IL-1b, ~15pg/mL IFN-g, and ~2pg/mL 
TNF-a.  However, cytokine levels significantly fell when unscarred I-HVFFs were 
induced into a scarred phenotype using TGF-β1 with IL-6 falling to ~45pg/mL (Figure 
4.4), IL-1b to ~0pg/mL, IFN-g to ~2pg/mL, and TNF-a to ~0pg/mL.  This shows that 
though TGF-β1, a cytokine itself,
[19]
 acts as a pro-fibrotic agent by up-regulating collagen 
expression in our I-HVFFs (Figure 4.3), in the context of inflammation, it acts as an anti-
inflammatory agent.  This has been seen in other cell lines,
[19, 20]
 but to our knowledge 
never before in vocal fold fibroblasts.  When dexamethasone was added to our TGF-β1 
scarred I-HVFFs it had no significant impact beyond the one already seen by TGF-β1 on 
IL-1b, IFN-g, or TNF-a implying no synergistic effect between the two for these three 
pro-inflammatory cytokines.  However, it did show a significant impact in further 
decreasing the pro-inflammatory cytokine IL-6 (Figure 4.4), which has been seen in other 
cell lines.
[21-23]
  We also observed that even at the end of the study on day 4 free dM 
maintained its anti-inflammatory effect on IL-6 only rising slightly above the level of the 
scarred I-HVFFs exposed to the dM loaded mPs (Figure 4.4).  This prolonged anti-
inflammatory effect was not expected as free dM was not able to have the same impact in 
pro-longing its anti-fibrotic affects without the aid of the microparticles.  Finally, we also 
observed that I-HVFFs treated with PLGA only microparticles elicited the same level of 
inflammatory response for the 4 pro-inflammatory cytokines tested as those treated with 







Figure 4.4 Of the 4 cytokines tested (IFN-g, IL-1b, TNF-a, and IL-6) dexamethasone 
only indicated a synergistic anti-inflammatory effect with TGF-β1 on IL-6.  Both free dM 
and dM loaded mPs were able to maintain dexamethasone’s additive anti-inflammatory 
effect on IL-6 over the long term.  Treatments with non-matching symbols are 
statistically different from each other according to a one-way ANOVA + Tukey post-hoc 
test; p < 0.05. 
 
In closing, treating vocal fold scarring is a challenging task due to the complex nature of 
this affliction.  However, we show that a route to overcoming this problem could be 
through the controlled release of an anti-scarring therapeutic like dM.  Such a method 
provides prolonged residency of dM thereby increasing its anti-fibrotic efficacy and 






this microparticle based delivery system to control the delivery of other important anti-
fibrotic agents.  We also would like to investigate the ability of the microparticles to 
maintain their residency at their initial injection site based on their increased size in 
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CHAPTER 5. SUMMARY OF MAJOR FINDINGS AND FUTURE WORK 
There exist limited clinical options to treat vocal fold scarring, and these treatments only 
seek to relieve the effects over the short term.  Thus, the underlying vocal fold scar itself 
remains causing long-term problems to an afflicted patient’s ability to phonate.  
Therapeutics have been developed to treat scar tissue, but the full potential of such 
therapeutics has yet to be achieved in part due to challenges in delivering and maintaining 
these therapeutics at the site of scarring.   
 
The overall goal of my dissertation research was to address this issue of effectively 
delivering therapeutics to an area of vocal fold scarring to facilitate healthy unscarred 
tissue regeneration.  To accomplish this goal the following aims were proposed and 
completed. 
 
In the first aim, chapter 2, we characterized our in vitro unscarred and scarred culture 
systems.  This was accomplished by elucidating the impact RGD integrin binding site 
concentration and cell phenotype had on directing extracellular matrix gene expression in 
vocal fold fibroblasts, and found that both had an effect.  With changes in fibroblast 






tested, except for HAS2 and DCN.  Meanwhile, variations in RGD integrin concentration 
impacted ECM gene expression only in specific phenotypes.  Unscarred I-HVFFs were 
unaffected by changes in RGD integrin concentration for all six ECM genes tested except 
HAS2 which saw down-regulation with addition of any RGD.  Scarred I-HVFFs were 
affected, with ELN gene expression being up-regulated as the concentration of RGD 
increased.  Similar results, albeit of smaller magnitude, were obtained for COL3A1 gene 
expression as well.  HAS2 expression was also impacted with a further down regulation 
in its expression at the highest RGD concentration in scarred I-HVFFs.  DCN, FN, & 
COL1A2 remained unchanged in scarred I-HVFFs with respect to changes in RGD 
concentration.  This knowledge is critical to have when developing bioactive materials in 
which healthy ECM component ratios and morphologies are regenerated through 
variation in biological cues, like RGD.  
 
In aim 2, chapter 3, we focused on developing an initial proof of concept nanoparticle 
based system that would provide multiple avenues for controlling release of a loaded 
therapeutic.  To do this a novel poly-lactic-co-glycolic acid (PLGA) core + poly(N-
isopropylacrylamide (pNIPAM)-co-acrylic acid (AAc) shell nanoparticle system was 
synthesized and characterized.  A critical characteristic of this system is the ability of the 
pNIPAM-co-AAc shell to prevent the aggregation of the PLGA cores during 
lyophilization without the need of cryo-protectants.  Secondly, the addition of the 
pNIPAM-co-AAc shell imbues the overall PLGA core + pNIPAM shell nanoparticle 
system with more dynamic properties including the ability to respond to environmental 






provides a functional handle used to append targeting ligands in an acrylic acid monomer 
concentration dependent manner.  Finally, results from in vitro experiments demonstrated 
the biocompatibility of these PLGA core + pNIPAM-co-AAc nanoparticles with cells. 
 
Finally, the third aim, chapter 4, sought to develop a controlled release therapeutic system 
capable of delivering an effective concentration of dexamethasone for a sustained period 
of time, in order to return scarred I-HVFFs back to a healthy unscarred state.  To 
accomplish this, hydrogel templated poly-lactic-co-glycolic acid (PLGA) microparticles 
were loaded with the corticosteroid dexamethasone.   Larger microparticles were used to 
guarantee a controlled delivery of an effective therapeutic dose.  Real-time PCR showed 
that only dexamethasone loaded microparticles proved effective at maintaining down 
regulation in the expression of COL3A1 and COL1A2, which are normally highly up-
regulated in scarred fibroblasts, over the long term.  While an ELISA showed that 
dexamethasone decreased the deposition of the inflammatory cytokine interleukin-6 over 
the long term, but had no impact on the other three cytokines tested.  
 
Based on the aforementioned findings the goal to develop an effective controlled delivery 
system for administering therapeutics for treating vocal fold scarring has been 
accomplished.  However, more work needs to be done before the delivery systems 
developed here are ready to make the leap from bench to bedside. 
 
In looking forward, it would potentially be highly advantageous to add a pNIPAM-co-






This would combine the advantages of the larger microparticle size, with its ability to 
more readily deliver an effective dose of therapeutic, with the many beneficial attributes, 
like targeting and protection during lyophilization based storage, of the pNIPAM-co-
acrylic acid shell.  Furthermore, with the addition of a shell another level of control over 
therapeutic release is available.  What also should be explored is whether the larger 
microparticle size anchors the particles within the tissue due to ECM entrapment.  If the 
larger size of the microparticles does not facilitate increased residence time of the drug 
loaded microparticles at a site of injection, then the targeting ability of the pNIPAM-co-
acrylic acid shell could facilitate anchoring at the site of injection.  The targeting ligands 
that could be used in this case are a collagen type I or collagen type III binding peptide or 
one could also explore using RGD as a targeting ligand.   
 
If the RGD targeting ligand option was explored, then it would also be interesting to see 
if any of the changes seen in ECM gene expression due to RGD concentration changes on 
a glass surface, from aim 1, would also be present when the RGD concentration was 
varied on a particle surface.  Furthermore, we hypothesize that an RGD targeting ligand 
could reduce the stress perception of I-HVFFs thereby helping facilitate the modulation 
of phenotype of scarred I-HVFFs back to an unscarred state.  This would be achieved as a 
result of the scarred I-HVFFs binding to the RGD ligands of the free floating, softer, 
polymer-based particles thereby reducing their perception of the stiff glass or plastic they 







Finally, one could look at assessing the impact free dexamethasone and dexamethasone 
loaded micropaticles, from aim 3, have on the expression of collagen in the in vitro 
scarred and unscarred culture systems described in aim 1.  Furthermore, one could also 
look at using these culture systems to investigate other ECM components, besides 
collagen, that play a role in scarring, like decorin.  Yet another way the culture systems 
could be used is to screen other anti-scarring agents, like pirfenidone, in both their free 
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